{"public_id":"cl_53500fe99876b28f71dbb327b54c2218","status":"active","superseded_by_public_id":null,"corpus_id":4228513,"text":"HO-3867 is a p53 mutant-reactivating drug with high clinical anticancer potential.","confidence":0.9,"paper":{"corpus_id":4228513,"title":"The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53","url":"https://sah.borca.ai/papers/4228513"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.9,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_0f1a025a933007da2d52362608a20f12","name":"clinical anticancer potential","description":"The potential of a compound to be developed for cancer treatment in clinical settings.","types":["therapeutic potential"],"url":"https://sah.borca.ai/concepts/co_0f1a025a933007da2d52362608a20f12"},{"public_id":"co_41c9f4a781637a9193fb327f6f2582e2","name":"HO-3867","description":"A curcumin analog investigated for its effects on mutant p53 activity and anticancer activity.","types":["compound","drug"],"url":"https://sah.borca.ai/concepts/co_41c9f4a781637a9193fb327f6f2582e2"},{"public_id":"co_7c4d8e27a6169725030e245713028cbd","name":"p53 mutant-reactivating drug","description":"A therapeutic agent designed to restore transcriptionally active wildtype-like function to mutant p53.","types":["drug mechanism","therapeutic class"],"url":"https://sah.borca.ai/concepts/co_7c4d8e27a6169725030e245713028cbd"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_53500fe99876b28f71dbb327b54c2218"}